Survodutide Results: What Studies Measured and When
What published studies measured for Survodutide, when those outcomes were measured, and what is still unproven.
What studies measured
Each outcome below comes from a published study, with its type and size, strongest design first. Animal and cell results are labelled as such and are not human results.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Body weight at week 76 (coprimary) | Body weight changed by -13.0% with 6.0 mg and -12.2% with 3.6 mg versus -5.4% with placebo at week 76 (treatment-regimen estimand). | Human RCTn = 725 | The New England journal of medicine 2026, PMID 42253238 |
| Body weight at week 76 (coprimary) | Body weight changed by -9.8% with 6.0 mg and -8.2% with 3.6 mg versus -3.9% with placebo. | Human RCTn = 752 | The New England journal of medicine 2026, PMID 42820639 |
| HbA1c | Glycated hemoglobin changed by -0.9 percentage points (3.6 mg) and -0.8 (6.0 mg) versus -0.2 with placebo. | Human RCTn = 752 | The New England journal of medicine 2026, PMID 42820639 |
| Liver fat reduction of 30% or more | 84.2% on survodutide versus 24.3% on placebo had a 30% or greater liver fat reduction (efficacy estimand); 68.5% versus 28.6% (treatment regimen estimand). | Human RCTn = 216 | Nature medicine 2026, PMID 42252333 |
| Body weight | Body weight changed by -12.2% with survodutide versus -1.0% with placebo (efficacy estimand). | Human RCTn = 216 | Nature medicine 2026, PMID 42252333 |
| Body weight at week 46 (primary) | Body weight changed by -14·9% with 4·8 mg, -13·2% with 3·6 mg, -12·5% with 2·4 mg and -6·2% with 0·6 mg versus -2·8% with placebo at week 46. | Human RCTn = 387 | The lancet. Diabetes & endocrinology 2024, PMID 38330987 |
| MASH improvement without worsening of fibrosis (primary) | MASH improved without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg) and 43% (6.0 mg) versus 14% with placebo. | Human RCTn = 293 | The New England journal of medicine 2024, PMID 38847460 |
| Liver fat reduction of 30% or more | A 30% or greater liver fat decrease occurred in 63%, 67% and 57% across doses versus 14% with placebo. | Human RCTn = 293 | The New England journal of medicine 2024, PMID 38847460 |
| HbA1c vs semaglutide | HbA1c fell by -1.46% with low-dose survodutide (DG2) and -1.47% with semaglutide. | Human RCTn = 413 | Diabetologia 2024, PMID 38095657 |
| Body weight | Body weight fell dose-dependently up to -8.7% (DG6), greater than with semaglutide (-5.3%) for survodutide 1.8 mg weekly or more. | Human RCTn = 413 | Diabetologia 2024, PMID 38095657 |
| Liver and metabolic markers in cirrhosis | Liver fat content, liver stiffness, liver volume and body weight were generally reduced after 28 weeks (non-randomised, open-label). | Human uncontrolled trial | Journal of hepatology 2024, PMID 38857788 |
| HbA1c | Survodutide reduced HbA1c by a weighted mean difference of -0.66% (95% CI -1.08 to -0.23) versus placebo. | Meta-analysisn = 1272 | Diabetes, obesity & metabolism 2025, PMID 40922121 |
| Waist circumference | Survodutide reduced body weight by a mean difference of -6.7 kg and waist circumference by -7.09 cm. | Meta-analysisn = 1272 | Diabetes, obesity & metabolism 2025, PMID 40922121 |
| Cholesterol, triglycerides and blood pressure | Modest reductions were noted in total cholesterol, triglycerides and blood pressure (no figures in the abstract). | Meta-analysisn = 1272 | Diabetes, obesity & metabolism 2025, PMID 40922121 |
| Weight, BMI and waist circumference | Survodutide reduced weight by a mean difference of -8.33 kg, BMI by -4.03 kg/m2 and waist circumference by -6.33 cm versus control (very high heterogeneity). | Meta-analysisn = 1029 | Diabetology & metabolic syndrome 2024, PMID 39508238 |
- Survodutide (BI 456906, Boehringer Ingelheim) is investigational and not FDA-approved as of 2 October 2026. Phase 3: SYNCHRONIZE-1 (obesity, PMID 42253238) and SYNCHRONIZE-2 (obesity with type 2 diabetes, PMID 42820639) report 76-week results; SYNCHRONIZE-MASLD (PMID 42252333) reports 48-week liver fat results. SYNCHRONIZE-CVOT is registered but no efficacy results were found.
- No half-life was found. The cirrhosis phase 1 trial (PMID 38857788) reports similar AUC and Cmax in cirrhosis versus healthy people but no half-life figure.
- No evidence was extracted for osteoporosis or other goals.
- The phase 2 MASH trial (38847460) and SYNCHRONIZE-MASLD (42252333) use different primary endpoints (histology versus MRI-PDFF liver fat) and cannot be compared directly.
Typical timeline
When the studies above measured their outcomes. This is the study schedule, not a promise of when anyone will notice a change.
| When | What was measured | Study type | Source |
|---|---|---|---|
| 76 weeks | Primary endpoints: percent change in body weight and 5% or more reduction | Human RCTn = 725 | The New England journal of medicine 2026, PMID 42253238 |
| 46 weeks | Primary endpoint: percentage change in bodyweight (20 weeks escalation, 26 weeks maintenance) | Human RCTn = 387 | The lancet. Diabetes & endocrinology 2024, PMID 38330987 |
| 48 weeks | Trial length (24-week escalation, 24-week maintenance) | Human RCTn = 293 | The New England journal of medicine 2024, PMID 38847460 |
| 16 weeks | Primary endpoint: absolute change in HbA1c | Human RCTn = 413 | Diabetologia 2024, PMID 38095657 |
Before-and-after photos
We don't publish before-and-after photos. They can't be verified, rarely show dose, diet or other drugs, and only the most dramatic results get posted.
Common questions
How long does Survodutide take to work?
The studies we summarise measured outcomes at set points, for example Primary endpoints: percent change in body weight and 5% or more reduction at 76 weeks; Primary endpoint: percentage change in bodyweight (20 weeks escalation, 26 weeks maintenance) at 46 weeks. Timelines outside studies vary.
Do you show Survodutide before and after photos?
No. Photos can't be verified, rarely show dose, diet or other drugs, and only the most dramatic ones get posted. We summarize measured outcomes instead.
More on Survodutide
Sources
- 1Survodutide Once Weekly for the Treatment of Adults with Obesity.The New England journal of medicine · 2026PMID 42253238Accessed 2 Oct 2026
- 2Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.The New England journal of medicine · 2026PMID 42820639Accessed 2 Oct 2026
- 3Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.Nature medicine · 2026PMID 42252333Accessed 2 Oct 2026
- 4Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology · 2024PMID 38330987Accessed 2 Oct 2026
- 5A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.The New England journal of medicine · 2024PMID 38847460Accessed 2 Oct 2026
- 6Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.Diabetologia · 2024PMID 38095657Accessed 2 Oct 2026
- 7Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.Journal of hepatology · 2024PMID 38857788Accessed 2 Oct 2026
- 8Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.Diabetes, obesity & metabolism · 2025PMID 40922121Accessed 2 Oct 2026
- 9Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2024PMID 39508238Accessed 2 Oct 2026
Found an error? Report a correction.